ClinicalTrials.gg

How we know

Every link on this study, and who decided it

The study on the left, the conditions and drugs this site links it to, and on each link the judgments that made or checked it, by day and by judge. The top row is the record itself: each new version seen since tracking began. Dashed lines are links the registry record does not make itself. Select a link to see everything judged on it, or a mark for one decision with its reason and evidence.

7 links0 made here, not in the record12 judgments2 judges (the rules as one: Rule based)2 record changes seen4 read an older version
Claude Opus 5.5Rule basedRecord updated on ClinicalTrials.govReplaced, or read an older version
Oct 19Oct 26Nov 2Nov 9Nov 16TodayNCT07332351Neoadjuvant IntravesicalNadofaragene FiradenovecWith Enfortumab Vedotin andPembrolizumab for theTreatment of MuscleInvasive Bladder Cancer,TRIFECTA TrialUniversity of WashingtonPhase 2 · not yet recruitingRECORDThe record itselfVersions seen nightly since Sep 25, 2…›Oct 26 · ClinicalTrials.gov record · Version of 2026-10-26Nov 13 · ClinicalTrials.gov record · Version of 2026-11-13Nov 13 · Rule based · Reading set asideNov 16 · Rule based · Read againRead againCONDITIONSUrinary Bladder NeoplasmsThe registry's MeSH filing›As of now · Rule based · Main conditionMain conditionDRUGSNadofaragene firadenovecIntervention entry›Nov 3 · Claude Opus 5.5 · TestedNov 18 · Rule based · TestedTestedEnfortumab vedotinIntervention entry›Nov 16 · Claude Opus 5.5 · Background · establishedNov 18 · Rule based · TestedBackground · establishedPembrolizumabIntervention entry›Nov 16 · Claude Opus 5.5 · Background · establishedNov 18 · Rule based · TestedBackground · establishedDurvalumabIntervention entry›Nov 3 · Claude Opus 5.5 · TestedTestedGemcitabineIntervention entry›Nov 3 · Claude Opus 5.5 · TestedTestedCisplatinIntervention entry›Nov 3 · Claude Opus 5.5 · TestedTested

Times are in your time zone; a day marked “day only” kept no time. The graph scrolls sideways on a narrow screen; every mark is also in the list below.

Nadofaragene firadenovec

From the registry record2 judgments on this link
Role in the study, from the registry to what was judged
RegistryEntry “Nadofaragene Firadenovec”the record gives no role
→judged=agrees
How the 2 judgments split100%of judgments with a known value say Tested
Tested · 2

All judgments on this study

WhenLinkJudgeDecisionState
Oct 26The record itselfClinicalTrials.gov recordVersion of 2026-10-26Record change
Nov 3Nadofaragene firadenovecClaude Opus 5.5TestedRead an older version
Nov 3DurvalumabClaude Opus 5.5TestedRead an older version
Nov 3GemcitabineClaude Opus 5.5TestedRead an older version
Nov 3CisplatinClaude Opus 5.5TestedRead an older version
Nov 13The record itselfClinicalTrials.gov recordVersion of 2026-11-13Record change
Nov 13The record itselfRule based · nightly checkReading set asideCurrent
Nov 16The record itselfRule based · nightly checkRead againCurrent
Nov 16Enfortumab vedotinClaude Opus 5.5Background · establishedCurrent
Nov 16PembrolizumabClaude Opus 5.5Background · establishedCurrent
Nov 18Nadofaragene firadenovecRule based · role ruleTestedCurrent
Nov 18Enfortumab vedotinRule based · role ruleTestedOverridden
Nov 18PembrolizumabRule based · role ruleTestedOverridden
As of nowUrinary Bladder NeoplasmsRule based · main-condition ruleMain conditionCurrent

The rules, in plain words

“Rule based” means one of these decided, not a model or a person. Each runs every night over every study.

Which drugs a study tests

Reads each treatment the study lists and the arms it is in. A drug only in the experimental arm is tested. A drug in every arm while something else changes between the arms is given beside it. A drug only in the control arm is the comparator. Placebo, procedures and usual care are known by name.

Where the whole record has been read, that reading's answer replaces the rule's.

What a study is mainly about

Starts from the first condition ClinicalTrials.gov files the study under. It moves to a narrower one only when the study's own title or listed conditions name it, and sets aside terms the registry often files by mistake. A study open to many cancers is not placed under one of them unless its title names it.

Checked against studies judged one by one; the study page says when it differs from the registry.

When a study changes after it was read

Every night, studies whose record changed are compared with the last reading. A change to sites or dates leaves the reading as it is; a reworded entry keeps it; a change to the treatments or conditions marks it to be read again.

Until it is read again, the page shows the last reading and says so.